Skip Navigation


JAC Advance Access originally published online on November 28, 2002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/1/199    most recent
dkg017v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lister, P. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lister, P. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 199-202
© 2003 The British Society for Antimicrobial Chemotherapy

Correspondence

Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones

Philip D. Lister*

Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178, USA

The first 10% of the full text of this article appears below.

Sir,

Garenoxacin (BMS-284756) is a new des-F(6) quinolone that exhibits enhanced potency against Streptococcus pneumoniae compared with clinically available fluoroquinolones.1 Although this antibiotic lacks the C-6 fluorine, its antibacterial mechanism of action against DNA gyrase appears to be the same as that of other quinolones.2 It is well established that the AUC/MIC ratio is an important pharmacodynamic parameter influencing quinolone efficacy, and AUC/MIC ratios of ~30 or higher have been shown to be sufficient to eradicate S. pneumoniae from in vitro pharmacodynamic models (IVPM).3,4 A similar minimum target has been reported for the eradication of S. pneumoniae from community-acquired respiratory tract infections.5 This study was designed to evaluate the impact of AUC/MIC ratios on the pharmacodynamics of garenoxacin.

Three isolates of S. pneumoniae were selected for this study. Susceptibility tests with levofloxacin . . . [Full Text of this Article]

Acknowledgements


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
G. G. Zhanel, J. James, S. Derkatch, N. Laing, A. M. Noreddin, and D. J. Hoban
Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae
J. Antimicrob. Chemother., July 1, 2006; 58(1): 112 - 116.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. H. Kiser, D. W. Hoody, M. D. Obritsch, C. O. Wegzyn, P. C. Bauling, and D. N. Fish
Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.
Antimicrob. Agents Chemother., June 1, 2006; 50(6): 1937 - 1945.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Van Wart, L. Phillips, E. A. Ludwig, R. Russo, D. A. Gajjar, A. Bello, P. G. Ambrose, C. Costanzo, T. H. Grasela, R. Echols, et al.
Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections
Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4766 - 4777.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Perez-Vazquez, F. Roman, B. Aracil, R. Canton, and J. Campos
In Vitro Activities of Garenoxacin (BMS-284756) against Haemophilus influenzae Isolates with Different Fluoroquinolone Susceptibilities
Antimicrob. Agents Chemother., November 1, 2003; 47(11): 3539 - 3541.
[Abstract] [Full Text] [PDF]